Sarcoma and Solid Tumors
Solid tumors are masses that can grow almost anywhere in the body with the exception of the blood (hematological cancer). Solid tumors as split into two categories: sarcomas and carcinomas.
Our research team looks for ways to decrease the size and impact of solid tumors, or to slow the growth of the tumor in the safest way possible. This is determined through a combination of inhibitors, radiation treatments, and other therapies. Our researchers also evaluate tumors through biopsies to better understand what the genetic make-up of the tumor is and how it can be treated.
Protocol ID: ADVL1711
Diseases: CNS Tumors, Ewing Sarcoma (EWS), High Grade Glioma (HGG), Osteosarcoma (OS), Rhabdomyosarcoma, and Sarcoma
Who Can Participate?: Replased/Refractory, ages 2 to 20
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: MCC19487
Diseases: Osteosarcoma (OS) and Sarcoma
Who Can Participate?: Replase/Refractory, ages 0 to 39
Lead Researcher: Bhuvana A. Setty, MD
Protocol ID: ARST1431
Disease: RMS
Who can participate?: Must be ≤ 40 yrs w/ newly dx RMS of any subtype, except adult-type pleomorphic, based upon institutional histopathologic classification, are eligible to enroll on the study based upon Stage, Group, and age, as defined by the protocol.
Lead Researcher: Mark A. Ranalli
Protocol ID: ARST1921
Disease: Sarcoma
Who Can Participate?: Relapse/Refractory, ages 1 to 17
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: ADVL1921
Disease: Solid tumors
Who can participate?: Age ≥2 and <21 years at the time of study entry. Histologically confirmed relapsed or refractory solid tumors.
Lead Researcher: Mark A. Ranalli
Protocol ID: AHEP1531
Disease: Hepatoblastoma
Who can participate?: Patients must be ≤ 30 years of age at the time of diagnosis. Patients in Group F must have a BSA ≥ 0.6 m2. Patients must be newly diagnosed with histologically-proven primary pediatric hepatic malignancies including hepatoblastoma or hepatocellular carcinoma, except as noted in Section 3.2.5 below. Patients with a diagnosis of hepatocellular neoplasm, not otherwise specified,should be classified and treated per hepatoblastoma treatment arms.
Lead Researcher: Mark A. Ranalli
Protocol ID: ALTE16C1
Disease: Solid Tumors
Who can participate?: Male patients must be ≥ 18 and ≤ 50 years of age at the time of enrollment.
Lead Researcher: Mark A. Ranalli
Protocol ID: APEC1621J
Disease: Solid Tumors
Who can participate?: Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment. Patients must have a body surface area ≥ 0.54 m2 at the time of study enrollment. Patient must have enrolled onto APEC1621SC and must have been given a treatment assignment to MATCH to APEC1621J based on the presence of an actionable mutation.
Lead Researcher: Mark A. Ranalli
Protocol ID: AREN03B2
Disease: Wilms tumor
Who Can Participate?: New diagnosis, ages 0 to 230
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: AREN1721
Disease: Wilms Tumor
Who can participate?: Patients must be ≥ 12 months at enrollment. Patients must have a Body Surface Area (BSA) ≥ 0.53 m2. Histologically confirmed unresectable or metastatic translocation morphology renal cell carcinoma diagnosed using WHO-defined criteria. Patients may be newly diagnosed or have received prior cancer therapy. Patients must have measurable disease, documented by clinical, radiographic, or histologic criteria as defined by RECIST v1.1.
Lead Researcher: Mark A. Ranalli
Protocol ID: MCC20320
Disease: Sarcoma
Who Can Participate?: New diagnosis, ages 0 to 40
Lead Researcher: Bhuvana A. Setty, MD
Protocol ID: ctDNA
Disease: Solid Tumor
Who can participate?: > 12 months of age at time of study enrollment to 50 years of age. Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed, localized or regionally disseminated Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) of bone or soft tissue OR Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed, non-pelvic, localized or regionally disseminated high-grade osteosarcoma.
Lead Researcher: Bhuvana A. Setty
Protocol ID: APEC1621I
Disease: Solid tumors
Who can participate?: Patient must have enrolled onto APEC1621SC and must have been given a treatment assignment to MATCH to APEC1621I based on the presence of
an actionable mutation as outlined in the protocol.
Lead Researcher: Mark A. Ranalli
Protocol ID: APEC1621H
Disease: Solid Tumors
Who can participate?: Prior enrollment on APEC1621SC
Ages >12 months and < 21 years of age
Must have Radiographically measurable disease
Enrollment after > 21 days after the last cytotoxic or myelosuppressive chemotherapy.
Lead Researcher: Mark A. Ranalli
Protocol ID: NANT2004-05
Disease: Neuroblastoma (NBL)
Who Can Participate?: Replase/Refractory, ages 0 to 99
Lead Researcher: Keri A. Streby, MD
Protocol ID: SALA-002-EW16
Disease: Desmoplastic small round cell tumor Ewing Sarcoma
Who can participate?: Patients aged 12 and up
Lead Researcher: Bhuvana Setty
Protocol ID: VYR-VSV2-101
Diseases: Colorectal cancer, Neuroendocrine tumor. and Pheochromocytoma
Who Can Participate?: Relapse/Refractory, ages 0 to 18
Lead Researcher: Timothy P. Cripe, MD, PhD
Protocol ID: APEC1621N
Diseases: Solid tumors
Who Can Participate?: Ages 1 to 21
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: APEC1621A
Disease: Solid Tumors
Who can participate?: Patients must be greater than 12 months of age and less than 21 years of age at the time of study enrollment
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: APEC1621B
Disease: Solid tumors
Who can participate?: Prior enrollment on APEC1621SC screening protocol. Ages > 21 months and <21 years of age. Must have Radiographically measurable disease. > 21 days after last dose of cytotoxic or myelosuppressive chemotherapy.
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: APEC1621D
Disease: Solid Tumors
Who can participate?: Ages > 2 - < 19 years
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: APEC1621F
Disease: Solid tumors
Who can participate?: No specific age requirement
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: APEC1621G
Disease: Solid tumor
Who can participate?: Patients must be < 30 years of age
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: APEC1621SC
Disease: Solid tumor
Who can participate?: Patients must be ≥ 12 months and ≤ 21 years of age at the time of study enrollment. Patients with recurrent or refractory solid tumors, including nonHodgkin lymphomas, histiocytoses (e.g. LCH, JXG, histiocytic sarcoma), and CNS tumors are eligible. Patients must have had histologic verification of malignancy at original diagnosis or relapse except in patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of CSF or serum tumor markers including alpha-fetoprotein or betaHCG.
Protocol ID: NCHB001
Disease: Solid tumors
Who can participate?: No specific age requirement
Lead Researcher: Bhuvana A. Setty, MD
Protocol ID: MCC18613
Disease: Sarcoma
Who can participate?: Patients must be age > 12 and ≤30 years, and have had a histologic diagnosis of osteosarcoma, Ewing sarcoma, or rhabdomyosarcoma or non-rhabdomyosarcoma soft tissue sarcoma either at diagnosis or relapse.
Protocol ID: GAIN
Disease: Solid tumors
Who can participate?: Age ≤ 30 years at time of initial qualifying solid tumor diagnosis.
Lead Researcher: Susan I. Vear, MD
Protocol ID: TVEC
Disease: Non-CNS Solid Tumor
Who can participate?: Subjects 2 to ≤ 21 years of age. Histologically or cytologically confirmed non-CNS solid tumor that recurred after standard/frontline therapy, or for which there is no standard/frontline therapy available.
Lead Researcher: Keri A. Streby, MD